Last reviewed · How we verify
Metolazone concurrently with furosemide
Metolazone and furosemide together act as synergistic diuretics that block sodium reabsorption at different nephron sites to produce enhanced fluid and electrolyte excretion.
Metolazone and furosemide together act as synergistic diuretics that block sodium reabsorption at different nephron sites to enhance fluid and electrolyte excretion. Used for Edema and fluid overload in heart failure, Edema associated with renal disease, Hypertension.
At a glance
| Generic name | Metolazone concurrently with furosemide |
|---|---|
| Also known as | Zaroxolyn |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Thiazide-like diuretic and loop diuretic combination |
| Target | Sodium-chloride cotransporter (NCC) and sodium-potassium-chloride cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Metolazone is a thiazide-like diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule, while furosemide is a loop diuretic that blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle. When used concurrently, they produce a synergistic diuretic effect that is more potent than either agent alone, particularly useful in patients with severe fluid overload or diuretic resistance.
Approved indications
- Edema and fluid overload in heart failure
- Edema in renal disease
- Hypertension
- Diuretic-resistant edema
Common side effects
- Hypokalemia
- Hyponatremia
- Hyperuricemia
- Ototoxicity (with high-dose furosemide)
- Dehydration
- Hypotension
- Hyperglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: